Precision Medicine
Precision medicine tailors treatments to the needs of individual patients by considering genetic, environmental and lifestyle factors. They can target the underlying causes of a patient’s condition, improve effectiveness, and reduce side effects.

Personalised Medicine: is it an Oil-Rush or Oil-Spill?
1 May 2020
Personalised medicine, also known as ‘precision’ or ‘stratified’ medicine, targets treatment by using genetics and/or biomarkers to identify patients or subgroups of patients who have distinct…

Our Contributions to the Economics of Personalised Medicine
7 March 2018
OHE has authored numerous papers on personalised medicine with contributions to value frameworks, innovations in pricing and cost effectiveness analyses.

Value and Cancer: Journal of Cancer Policy Special Issue
25 January 2017
A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.

OHE’s Paula Lorgelly Appointed as a Visiting Professor at King’s College London
20 June 2016
Paula Lorgelly has accepted an appointment as a Visiting Professor in the Division of Cancer Studies at King’s College London.

OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
29 October 2014
ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The…

Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
18 December 2013
Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in…

Personalised Medicine: Economic Incentives for Evidence Generation
28 October 2013
Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison,…

OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
6 August 2013
OHE was involved in several sessions at the 9th World Congress of the International Heath Economics Association (iHEA). Prof Adrian Towse, OHE’s Director, and Prof Lou…